# Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

> **NCT03227419** · PHASE4 · UNKNOWN · sponsor: **Lille Catholic University** · enrollment: 224 (estimated)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Tocilizumab Prefilled Syringe
- **DRUG:** Abatacept Prefilled Syringe

## Key facts

- **NCT ID:** NCT03227419
- **Lead sponsor:** Lille Catholic University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-22
- **Primary completion:** 2024-09
- **Final completion:** 2024-11
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227419, "Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03227419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*